NovoCure (NVCR) Convertible Debt (2023 - 2024)
NovoCure recorded quarterly Convertible Debt of $556.5 million in Q2 2024, down 2.16% quarter-over-quarter from $568.8 million in Q4 2023.
NovoCure's Convertible Debt history runs 2 years deep, the most recent figure standing at $556.5 million for Q2 2024.
- In Q2 2024, Convertible Debt changed N/A year-over-year to $556.5 million; the TTM figure through Jun 2024 stood at $556.5 million (changed N/A YoY), while the FY2023 annual figure was $568.8 million, changed N/A from the prior year.
- Convertible Debt came in at $556.5 million for Q2 2024 at NovoCure, down from $568.8 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $568.8 million in Q4 2023 to a low of $556.5 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 556.51 Mn |
| Dec 31, 2023 | 568.82 Mn |